ASIS for GAMMAGARD in Primary Immunodeficiency

"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."

"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."

Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.

Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.

Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.

Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .

subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.

Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.

subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.

Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.

subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.

Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.

(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.

Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.

subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.

Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.

subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.

Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.

subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.

Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24

(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.

Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.

subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.

Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.

subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.

subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.

Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.

(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.

Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.

subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12

Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12

subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12

Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12

subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12

Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12

(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12

Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.

subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.

Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.

subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.

Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.

subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.

Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.

(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.

Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.

subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.

Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.

subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.

subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.

Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.

(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.

Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain

Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.

Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.